MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
0.6257
+0.0046
+0.74%
Pre Market: 0.6257 0 0.00% 07:03 09/30 EDT
OPEN
0.6300
PREV CLOSE
0.6211
HIGH
0.6359
LOW
0.6118
VOLUME
9.86K
TURNOVER
0
52 WEEK HIGH
2.538
52 WEEK LOW
0.1611
MARKET CAP
152.33M
P/E (TTM)
-0.7211
1D
5D
1M
3M
1Y
5Y
1D
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 156%
Barron‘s · 1d ago
Kodiak Sciences Stock Surges 102% After Eye-Disease Drugs Pass Key Trial
Barron‘s · 1d ago
Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial
Barron‘s · 2d ago
Weekly Report: what happened at OTLK last week (0921-0925)?
Weekly Report · 2d ago
Weekly Report: what happened at OTLK last week (0914-0918)?
Weekly Report · 09/21 09:47
Outlook Therapeutics Sets U.S. Price for LYTENAVA
TipRanks · 09/18 21:20
Weekly Report: what happened at OTLK last week (0907-0911)?
Weekly Report · 09/14 09:50
Outlook Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 09/11 10:14
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.